Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.

European journal of endocrinology - 1 Sept 2011

Durante Cosimo, Tallini Giovanni, Puxeddu Efisio, Sponziello Marialuisa, Moretti Sonia, Ligorio Claudia, Cavaliere Antonio, Rhoden Kerry J, Verrienti Antonella, Maranghi Marianna, Giacomelli Laura, Russo Diego, Filetti Sebastiano

Abstract excerpt

OBJECTIVE: Tyrosine kinase inhibitors (TKIs) are evaluated for treatment of radioiodine refractory thyroid cancer. Their effects in this setting are based on blockade of proangiogenic signaling mediated by receptors for vascular endothelial growth factors (VEGFs) and platelet-derived growth factors (PDGF). Most TKIs also block other cancer-relevant kinases, such as B-type Raf kinase (BRAF), which are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenic Proteins
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microcirculation

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Receptors, Vascular Endothelial Growth Factor

Share to Thyroid Cancer, Papillary

Share to Thyroid Gland

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 21653734
DOI: 10.1530/EJE-11-0283

Genes

BRAF
VEGFA
MVD
PDGFB
PDGFRB

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.PMID 21653734Read ↗

Influence of the BRAF V600E Mutation on Expression of Vascular Endothelial Growth Factor in Papillary Thyroid CancerSemantic proximity Read ↗

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.Semantic proximity Read ↗

Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop.Semantic proximity Read ↗

BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?Semantic proximity Read ↗

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Semantic proximity Read ↗

Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.Semantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

Role of BRAF in thyroid oncogenesis.Semantic proximity Read ↗

BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer ProgressionSemantic proximity Read ↗

The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.